- Home
- ULS vs ROIV Comparison
ULS vs ROIV Comparison
Compare ULS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULS
- ROIV
- Stock Information
- Founded
- ULS 1894
- ROIV 2014
- Country
- ULS United States
- ROIV United Kingdom
- Employees
- ULS N/A
- ROIV N/A
- Industry
- ULS
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ULS
- ROIV Health Care
- Exchange
- ULS Nasdaq
- ROIV Nasdaq
- Market Cap
- ULS 14.6B
- ROIV 7.8B
- IPO Year
- ULS 2024
- ROIV N/A
- Fundamental
- Price
- ULS $71.08
- ROIV $11.20
- Analyst Decision
- ULS Buy
- ROIV Buy
- Analyst Count
- ULS 7
- ROIV 4
- Target Price
- ULS $69.43
- ROIV $17.50
- AVG Volume (30 Days)
- ULS 787.5K
- ROIV 7.2M
- Earning Date
- ULS 07-30-2025
- ROIV 08-07-2025
- Dividend Yield
- ULS 0.73%
- ROIV N/A
- EPS Growth
- ULS 28.34
- ROIV N/A
- EPS
- ULS 1.67
- ROIV N/A
- Revenue
- ULS $2,905,000,000.00
- ROIV $29,053,000.00
- Revenue This Year
- ULS $6.76
- ROIV $2.64
- Revenue Next Year
- ULS $6.04
- ROIV $378.09
- P/E Ratio
- ULS $42.63
- ROIV N/A
- Revenue Growth
- ULS 6.84
- ROIV N/A
- 52 Week Low
- ULS $41.69
- ROIV $8.73
- 52 Week High
- ULS $73.98
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- ULS N/A
- ROIV 51.38
- Support Level
- ULS N/A
- ROIV $10.71
- Resistance Level
- ULS N/A
- ROIV $11.82
- Average True Range (ATR)
- ULS 0.00
- ROIV 0.31
- MACD
- ULS 0.00
- ROIV -0.06
- Stochastic Oscillator
- ULS 0.00
- ROIV 44.14
About ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.